When will tremfya be generic?

Short answer: there isn’t a generic Tremfya yet.

What that means:
- Tremfya (guselkumab) is a monoclonal antibody, a biologic. For biologics, “generics” aren’t available in the same way as small-molecule drugs. Instead, companies can develop biosimilars.
- As of now, no FDA-approved guselkumab biosimilar has been released in the U.S. or most other markets.

When could a biosimilar become available?
- Biosimilars for Tremfya would face patent protections and data exclusivity. Tremfya was approved in 2017, and there are protections that typically push biosimilar competition several years after that.
- A rough timeline often cited is that biosimilar competition for a major biologic might appear around the late 2020s to early 2030s, but this depends on patent outcomes, litigation, and regulatory decisions. It could be earlier or later depending on those factors.

If you’d like, I can help you check the current status or point you to reliable sources (FDA biosimilars page, Janssen announcements) for the latest updates. Also, if cost is a concern, I can share general options like patient assistance programs or alternative therapies to discuss with your doctor.